Related Experiment Videos
Tamoxifen, screening and new oestrogen receptor modulators
1Department of Obstetrics and Gynaecology, Algemene Kliniek St.-Jan, Broekstraat 104, Brussels, B-1000, Belgium.
Summary
Tamoxifen effectively treats breast cancer but can cause uterine lesions. Screening is recommended for some users, balancing risks and benefits, while newer drugs like raloxifene show uterine neutrality.
Area of Science:
- Oncology
- Pharmacology
- Gynecology
Background:
- Tamoxifen, a selective estrogen receptor modulator (SERM), is a cornerstone in breast cancer treatment.
- It exhibits anti-estrogenic effects in breast tissue and estrogenic effects in bone and cardiovascular systems.
- Tamoxifen use is associated with an increased incidence of uterine lesions, both benign and malignant.
Purpose of the Study:
- To review the literature on tamoxifen-induced endometrial lesions.
- To evaluate the evidence for and against screening for these lesions in tamoxifen users.
- To compare the uterine effects of tamoxifen with newer SERMs like raloxifene.
Main Methods:
- Literature review of studies on tamoxifen and endometrial pathology.
- Analysis of evidence regarding the cost-effectiveness of endometrial screening.
- Comparison of endometrial safety profiles between tamoxifen and raloxifene.
Main Results:
- Endometrial thickening is common in tamoxifen users, often requiring further investigation.
- Routine endometrial screening is not cost-effective for all breast cancer patients on tamoxifen.
- Raloxifene, another SERM, demonstrates a neutral effect on the uterus in initial studies.
Conclusions:
- While tamoxifen is crucial for breast cancer, its endometrial risks necessitate careful consideration.
- Selective screening may be advisable for specific tamoxifen users, particularly after 3 years of treatment.
- Emerging SERMs like raloxifene offer a potentially safer alternative regarding uterine side effects.